Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27303075
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Drug Monographs: Daratumumab and Osimertinib
#MMPMID27303075
Solimando DA Jr
; Waddell JA
Hosp Pharm
2016[Apr]; 51
(4
): 288-92
PMID27303075
show ga
The complexity of cancer chemotherapy requires pharmacists be familiar with the
complicated regimens and highly toxic agents used. This column reviews various
issues related to preparation, dispensing, and administration of antineoplastic
therapy, and the agents, both commercially available and investigational, used to
treat malignant diseases. Questions or suggestions for topics should be addressed
to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201
Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J.
Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology
Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander
Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.